Aelis Farma: Availability of the Description of the Share Buyback Program
21 Junho 2023 - 1:00PM
Business Wire
Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a
clinical-stage biopharmaceutical company specialized in the
development of treatments for brain diseases, announces that the
availability of the description of the share buyback program
authorized by the Annual General Meeting of May 24, 2023.
Pursuant to Article L. 22-10-62 et seq. of the French Commercial
Code, the Combined General Meeting of shareholders authorized on
May 24, 2023, in its 10th resolution, the Board of Directors to
implement a share buyback program of the Company, with powers to
subdelegate in accordance with the law.
In accordance with Article 241-3 of the General Regulation of
the Autorité des Marchés Financiers (AMF), the description of the
share buyback program is included in the Company's Universal
Registration Document, which has been filed with the AMF on April
26, 2023, under number R.23-018. This document is available on the
Company's website at: https://www.aelisfarma.com/investors.
***
About AELIS FARMA
Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical
company that is developing a new class of drugs, the Signaling
Specific inhibitors of the CB1 receptor of the endocannabinoid
system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based
on the discovery of a natural brain defense mechanism by the team
led by Dr. Pier Vincenzo Piazza, the Company’s CEO, when he was
director of Neurocentre Magendie of the INSERM in Bordeaux. By
mimicking this natural mechanism, CB1-SSi appear to selectively
inhibit the disease-related activity of the CB1 receptor without
disrupting its normal physiological activity. CB1-SSi have
consequently the potential to provide new treatments for several
brain diseases.
Aelis Farma is currently developing two first-in-class
clinical-stage drug candidates: AEF0117 for the treatment of CUD,
currently being tested in a phase 2b study in the United States;
and AEF0217 for cognitive disorders, including those of Down
Syndrome (Trisomy 21), currently in a phase 1/2 study people with
Down syndrome in Spain. The Company also has a portfolio of
innovative CB1-SSi for the treatment of other disorders associated
with a dysregulation of the activity of the CB1 receptor.
Aelis Farma draws on the talents of more than 20 highly
qualified employees.
For more information, visit www.aelisfarma.com and follow
us on LinkedIn and Twitter.
ISIN: FR0014007ZB4 Ticker: AELIS B Compartment
of Euronext Paris
Disclaimer
Forward-looking statements Some information contained in
this press release are forward-looking statements, not historical
data. These forward-looking statements are based on current
beliefs, expectations, and assumptions, including, but not limited
to, assumptions about Aelis Farma's current and future strategy and
the environment in which Aelis Farma operates. They involve known
and unknown risks, uncertainties, and other factors, which may
cause actual results, performance, or achievements, or industry
results or other events, to differ materially from those described
or implied by such forward-looking statements. These risks and
uncertainties include those set out and described in detail in
Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration
Document approved by the Autorité des Marchés Financiers on April
26, 2023, under number R.23-018.
These forward-looking statements are made only as of the date of
this press release and Aelis Farma expressly disclaims any
obligation or undertaking to release any updates or corrections to
the forward-looking statements included in this press release to
reflect any change in expectations or events, conditions, or
circumstances on which any such forward-looking statement is based.
Forward-looking information and statements are not guarantees of
future performance and are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond Aelis Farma's control. Actual results could differ
materially from those described in, or implied or projected by,
forward-looking information and statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230621698516/en/
AELIS FARMA Pier Vincenzo Piazza CEO
contact@aelisfarma.com
NewCap Dusan Oresansky/Aurélie Manavarere Investor
Relations aelis@newcap.eu +33 1 44 71 94 92
NewCap Arthur Rouillé Media Relations aelis@newcap.fr +33
1 44 71 00 15
Aelis Farma (EU:AELIS)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Aelis Farma (EU:AELIS)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025